Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 2/20 | 1.00 |
| ▸ | HTR3B | O95264 | 2/20 | 1.00 |
| ▸ | HTR3A | P46098 | 2/20 | 1.00 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 1.00 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 14/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1714119 | 0.98 | HTR3A (0.97) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL5374136 | 0.90 | HTR3A (0.82) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL2869866 | 0.87 | HTR3E (0.77) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL31651894 | 0.87 | HTR3E (0.77) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5370408 | 0.83 | HTR3E (0.71) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL4658417 | 0.82 | HTR3E (0.69) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL4336114 | 0.82 | HTR3E (0.69) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL31652018 | 0.82 | HTR3A (0.69) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL3973132 | 0.82 | HTR3A (0.69) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL2349863 | 0.82 | HTR3A (0.69) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3468955-B1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3468955-B1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-01-06 | — | — | EP | disclosed |
| US-10829478-B2 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | GALAPAGOS NV (BE) | 2020-11-10 | — | — | US | disclosed |
| US-10829478-B2 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | GALAPAGOS NV (BE) | 2020-11-10 | — | — | US | disclosed |
| US-20190315719-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-10-17 | — | — | US | disclosed |
| US-20190315719-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-10-17 | — | — | US | disclosed |
| WO-2017211666-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2017-12-14 | — | — | WO | disclosed |
| CN-103936650-B | Acid imide Phenylpiperazine derivatives and salt, preparation method and purposes | GUANGZHOU MEDICAL UNIVERSITY (CN) | 2016-01-20 | — | — | CN | disclosed |
| US-9133145-B2 | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| WO-1996021648-A1 | NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 1996-07-18 | — | — | WO | disclosed |
| EP-0711757-A1 | 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy -pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists | F. Hoffmann-La Roche AG (CH) | 1996-05-15 | — | — | EP | disclosed |
| EP-0522915-B1 | Pyrimidine-4-carboxamide derivatives, their preparation and their use in therapeutics | SYNTHELABO (FR) | 1996-03-13 | — | — | EP | disclosed |
| US-5420130-A | Adrenergic blocking agents | SYNTHELABO (FR) | 1995-05-30 | — | — | US | disclosed |
| EP-0625514-A1 | 2-Amino-pyrazin-5-carboxamid derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1994-11-23 | — | — | EP | disclosed |
| CN-1079738-A | Heterobicyclic compounds | RECORDATI CHEM PHARM (CH) | 1993-12-22 | — | — | CN | disclosed |
| US-5244901-A | Multistage preparation by starting with a phenylpiperazine and an epoxide or chloro alcohol containing a phthalimido group; use to treat disorders involving hyperactivity of the alpha 1-adrenergic system | SYNTHELABO (FR) | 1993-09-14 | — | — | US | disclosed |
| WO-1993017007-A1 | HETEROBICYCLIC COMPOUNDS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 1993-09-02 | — | — | WO | disclosed |
| EP-0558245-A1 | Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1993-09-01 | — | — | EP | disclosed |
| EP-0522915-A1 | Pyrimidine-4-carboxamide derivatives, their preparation and their use in therapeutics | SYNTHELABO (FR) | 1993-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315719-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | ADAMTS5, ADAMTS4, ADAMTS1 | HTR3E 381/4885HTR3B 576/4885HTR3A 689/4885 |
| US-10829478-B2 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | ADAMTS5, ADAMTS4, ADAMTS1 | HTR3E 381/4885HTR3B 576/4885HTR3A 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.